La Jolla Pharmaceutical Company

Research-based biopharmaceutical company targeting at B-cell related autoimmune diseases such as Lupus and thrombosis; DNA contract manufacturing. La Jolla Pharmaceutical Company is focused on the research and development of therapeutic compounds to treat antibody-mediated autoimmune diseases. The Company uses its proprietary Tolerance Technology® to design novel therapeutic molecules to shut down faulty B cells and arrest the production of disease-causing antibodies. By treating the underlying cause of disease, the Company believes that Tolerance Technology will lead to products with improved therapeutic benefit and fewer side effects than currently available therapies. The Company is developing targeted therapeutics for major diseases and conditions caused by antibodies, such as lupus, antibody-mediated thrombosis, a clotting disorder associated with stroke, myocardial infarction, deep-vein thrombosis, and recurrent fetal loss, and organ rejection in xenotransplantation.

Activity:

- Contract Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Cardiovascular
- Reproductive Health
- Stroke

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: